Central & Peripheral Nervous System: Overview D₁ selective and mixed D₁/D₂ dopaminergic compounds: Structural diversity and recent advances

Abstract

CNS disorders like schizophrenia are postulated to arise from an impairment of one or more neurotransmitter or neuromodulatory regulatory mechanisms. Symptomology is partially ameliorated by current therapies, sometimes exhibiting enhanced antipsychotic potential or reduced side-effect profile (i.e., clozapine), a variety of hypotheses have arisen as to necessary and sufficient receptor affinities responsible for atypical activity. This review emphasises compound classes that have potent Di dopaminergic receptor affinity, either in selective form or combined with varying levels of D₂ receptor affinity. Structural diversity within this set of compounds provides insight into the similarities and differences between these two categories of dopaminergic receptors.